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Abstract
Background: Our objective was to evaluate the influence of liver metastasis on survival after pulmonary
metastasectomy in patients with colorectal cancer (CRC).
Methods: We retrospectively reviewed a total of 524 patients and were classified into two groups based on the
presence of liver metastasis. Group HM + PM (n = 106) included patients who previously received a hepatic
metastasectomy and then received pulmonary metastasectomy. Group PM (n = 418) included patients who only
received pulmonary metastasectomy with no liver metastasis.
Results: There were more male patients (70 vs. 57 %; P = 0.02) and more patients with colon cancer (60 vs. 42 %,
P = 0.001) in group HM + PM than in group PM. Otherwise, there was no significant difference between the two
groups in clinicopathologic characteristics and extent of surgery. The 5-year overall survival (OS) and disease-free
survival (DFS) rates were 58 and 31 %, respectively. There was no significant difference in OS (group HM + PM,
54 % vs. group PM, 59 %; P = 0.085) and in DFS (group HM + PM, 28 % vs. group PM, 32 %; P = 0.12). For the
entire patient cohort, a multivariate analysis revealed that the presence of liver metastasis, CRC T and N stages,
disease-free interval, and number and size of lung metastases were significantly associated with OS and DFS.
Conclusions: Our findings suggest that previous or present liver metastasis should not exclude a patient from
pulmonary metastasectomy. When lung metastasis is detected in patients with a history of hepatic metastasectomy,
pulmonary metastasectomy is still a viable treatment option especially in patients with a long disease-free interval
and a small number of lung metastases.
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Background
Lung metastasis in patients with colorectal cancer (CRC)
suggests the possibility of widespread hematogenous
dissemination of cancer, which needs to be treated with
systemic chemotherapy [1]. However, unsatisfactory
outcomes of chemotherapy for CRC patients with lung
metastases have provided a basis for surgical resection of
lung metastases [2]. Despite doubts about the role of
local treatment for systemic metastasis, many surgeons
have performed pulmonary metastasectomy in properly
selected patients with reported 5-year survival rates
ranging from 27 to 68 % [3–6].
However, it is controversial whether pulmonary metas-
tasectomy is still indicated for patients with a history of
hepatic metastasectomy. It also remains unknown
whether patients undergoing both hepatic and pulmonary
metastasectomies have comparable survival outcomes to
those undergoing pulmonary metastasectomy only. Some
authors demonstrated that a previous hepatic metastasect-
omy increased the risk of death in patients undergoing
pulmonary metastasectomy [7–10], whereas most studies
have reported that a history of liver metastasis at the time
of pulmonary metastasectomy is not an adverse factor
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impairing survival [6, 8, 11–17]. Therefore, it should be
noted that confining the candidates for metastasectomy to
patients with single-organ metastasis might deny some
patients a chance for long-term survival.
In our institution, we aggressively tried to perform
pulmonary metastasectomy even in patients with a his-
tory of liver metastases as long as those candidates fulfill
the criteria for pulmonary metastasectomy and liver me-
tastases had been completely resected. The objective of
this study was to evaluate whether a history of hepatic
metastasectomy influences survival in CRC patients
undergoing pulmonary metastasectomy by comparing
treatment outcomes between patients with and without
a history of hepatic metastasectomy. In addition, we
performed prognostic factor analyses in order to find
which factors affected survival.
Methods
Between January 1994 and December 2012, a total of
532 consecutive patients underwent pulmonary metasta-
sectomy for lung metastases of CRC at our institution.
Among these, 106 patients underwent metastasectomy
for lung metastases detected during follow-up after suc-
cessful hepatic metastasectomy (n = 102) or underwent
both hepatic and pulmonary metastasectomies simultan-
eously (n = 4) (group HM + PM). The remaining 418
patients received pulmonary metastasectomy only
without a history of extrapulmonary metastasis or liver
metastases (group PM). Patients were excluded if they
had metastasectomy for liver metastases detected during
follow-up after successful pulmonary metastasectomy
(n = 8). The indication of pulmonary metastasectomy
were (1) control of the primary CRC, (2) no extrapulmon-
ary metastases, (3) completely resectable lung metastases
at preoperative imaging studies, and (4) sufficient cardio-
pulmonary reserve for pulmonary metastasectomy. To
ensure that the indication of pulmonary metastasectomy
was fulfilled, patients need to undergo chest computed
tomography (CT) and abdomen CT and/or positron
emission tomography scan preoperatively. Their medical
records were retrospectively reviewed to assess clinical
characteristics, early postoperative outcomes, recurrence
pattern, and survival. This study was reviewed and
approved by the Institutional Review Board of Samsung
Medical Center.
After pulmonary metastasectomy, patients were regu-
larly evaluated by chest CT every 3 to 4 months for the
first 2 years following surgery and then every 6 months
thereafter. Serum carcinoembryonic antigen (CEA) level
was routinely checked at every outpatient visit. When
the extrapulmonary recurrence was suspected, we tried
to obtain histological or unequivocal radiological proof.
If pulmonary recurrence was considered resectable,
aggressive surgical resection was carried out.
Descriptive statistics were used to assess patient
demographic characteristics and outcomes. Normally
distributed continuous data were expressed as means ±
standard deviations. Categorical data were expressed as
counts and proportions. Student’s t tests or Wilcoxon
rank-sum test, depending on the normality of distribu-
tion, and the χ2 test or Fisher’s exact tests were used to
compare continuous and categorical variables, respect-
ively. One-way analysis of variance or Kruskal-Wallis
test, depending on the normality of distribution, was
used to compare the continuous variables among three
groups. The disease-free interval (DFI) was calculated as
the interval between the date of CRC resection and the
date of pulmonary metastasectomy. Overall survival
(OS) was defined as the time from the date of pulmon-
ary metastasectomy until the last date of follow-up for
patients who remained alive or until death. Disease-free
survival (DFS) was defined as the time from the date of
pulmonary metastasectomy to recurrence or death.
Survival curves were prepared using the Kaplan-Meier
method and were compared univariately using the log-
rank test. All statistical tests were two-sided with a
significance level set at 0.05 and were performed using




Patient characteristics are summarized in Table 1. The
study included 314 men (60 %) and 210 women (40 %)
with a mean age of 59 years (range, 30 to 83 years).
There were more male patients in group HM + PM than
in group PM (70 vs. 57 %, P = 0.02). With regard to the
location of primary tumor, more patients in group HM +
PM had colon cancer (60 vs. 42 %, P = 0.001) compared
with group PM in which there were more patients with
rectal cancer. Otherwise, there was no statistically signifi-
cant difference between the two groups in terms of age at
the time of pulmonary metastasectomy, pathologic stage
of primary tumor, number of lung metastases, size of the
largest lung metastasis, extent of pulmonary resection,
thoracoscopic surgery, and adjuvant chemotherapy.
Details of surgical techniques are shown in Table 2.
Treatment outcomes
Postoperative complications occurred in 22 patients
(4.2 %), including pneumothorax in six patients,
arrhythmia in six, and prolonged air leak in six. Patients
in group HM + PM (7.6 %) experienced complications
more frequently than in group PM (3.4 %), but there
was no statistically significant difference (P = 0.098). In-
hospital mortality occurred in one patient from group
HM + PM (0.19 %) and the cause of death was acute
respiratory distress syndrome.
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The mean follow-up duration was 45 months (0.2 to
217 months). At the end of follow-up, 176 of 524
patients (34 %) had died, and the remaining 348 patients
(66 %) were alive. The median OS time was 91.5 months
(95 % confidence interval (CI) 64.9~126.3), and OS rate
at 5 years was 58 %. There was no significant difference
in the 5-year OS rates between the two groups (group
HM + PM, 54 % vs. group PM, 59 %; P = 0.085; Fig. 1).
During follow-up, 286 patients (55 %) developed recur-
rence and of these, 248 (86.7 %) had distant metastasis.
Of these, 41 patients underwent repeated pulmonary
metastasectomy for recurrent lung metastases since they
fulfilled the criteria of pulmonary metastasectomy. Data
regarding recurrence pattern are summarized in Table 3.
The median DFS time was 24.9 months (95 % CI
21.2~27.5), and DFS rate at 5 years was 31 %. There was
no significant difference in the 5-year DFS rates between
the two groups (group HM + PM, 28 % vs. group PM,
32 %; P = 0.12; Fig. 2).
Prognostic factor analysis
To better understand the factors associated with im-
proved outcomes, univariate and multivariate analyses
were performed and detailed in Tables 4 and 5. For the en-
tire patient population, history of hepatic metastasectomy
before pulmonary metastasectomy, advanced pathologic T
and N stage of primary CRC, DFI (<12 months), number
of lung metastases, and size of the largest lung metastasis
were independent prognostic factors associated with
worse OS and DFS (Table 4). When a prognostic factor
analysis was confined to patients who had a history of
previous hepatic metastasectomy (group HM + PM), DFI
(<12 months) and number of lung metastases were
independent prognostic factors associated with worse OS
and DFS (Table 5).
Table 1 Patients characteristics
All patients
(n = 524)





No. (%) No. (%) No. (%)
Age at PM
(year, mean)
59.2 (30–83) 59.8 (30–83) 59.1 (31–82) 0.427
Sex 0.02
Male 314 (40.1) 74 (30.2) 240 (57.4)




Colon 239 (45.6) 64 (60.4) 175 (41.9)
Rectum 285 (54.4) 42 (39.6) 243 (58.1)
T stage of CRC 0.703
pT1 11 (2.1) 2 (1.9) 9 (2.2)
pT2 45 (8.6) 7 (6.6) 38 (9.1)
pT3 345 (65.8) 75 (70.8) 270 (64.6)
pT4 123 (23.5) 22 (20.8) 101 (24.2)
N stage of CRC 0.839
pN0 155 (29.6) 34 (32.1) 121 (28.9)
pN1 204 (38.9) 39 (36.8) 165 (39.5)
pN2 164 (31.3) 33 (31.1) 131 (31.3)




<12 months 112 (21.4) 23 (21.7) 89 (21.3)




Unilateral 425 (81.1) 85 (80.2) 340 (81.3)




Single 349 (66.6) 66 (62.3) 283 (67.7)
Multiple 175 (33.4) 40 (37.7) 135 (32.3)
Adjuvant
chemotherapy
376 (71.8) 83 (78.3) 293 (70.1) 0.094
PM pulmonary metastasectomy, CRC colorectal cancer
aDisease-free interval was calculated as the interval between the date of
colorectal cancer resection and the date of pulmonary metastasectomy
Table 2 Details of surgical techniques
All patients
(n = 524)





No. (%) No. (%) No. (%)
Extent of PM 0.35
Precision excision 20 (3.8) 5 (4.7) 15 (3.6)
Wedge resection 368 (70.2) 77 (72.6) 291 (69.6)
Segmentectomy 37 (7.1) 4 (3.8) 33 (7.9)
Lobectomy 93 (17.8) 18 (17) 75 (17.9)
Bilobectomy 4 (0.8) 1 (0.9) 3 (0.7)
Sleeve resectiona 2 (0.4) 1 (0.9) 1 (0.2)
Extent of HM
Chemotherapy 6 (5.7)











298 (56.9) 61 (57.6) 237 (56.7) 0.875
Mediastinal LND 140 (26.7) 28 (26.4) 112 (26.8) 0.937
PM pulmonary metastasectomy, HM hepatic metastasectomy, RFA
radiofrequency ablation, TACE transarterial chemoembolization, LND lymph
node dissection
aSleeve resection included one sleeve lobectomy and one sleeve bilobectomy
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Discussion
One of the most important prerequisites is that there
should be no extrapulmonary metastasis when consider-
ing pulmonary metastasectomy in CRC patients with
lung metastases [3]. The presence of liver metastasis in
addition to lung metastasis increases the probability of
widespread hematogenous tumor dissemination, which
may obviate the role of metastasectomy in patients with
lung metastases. However, when patients with a history
of completely resected liver metastases are diagnosed
with lung metastases, it remains unknown if they would
benefit from pulmonary metastasectomy or not. Is
pulmonary metastasectomy justified in these patients? In
order to answer this question, we conducted this study
comparing survival between patients with a history of
hepatic metastasectomy (group HM + PM) and those
without (group PM). By this comparative analysis, we
tried to evaluate whether a history of hepatic metasta-
sectomy influences survival in CRC patients undergoing
pulmonary metastasectomy. In the present study, there
was no significant difference in the 5-year OS and DFS
rates between the two groups. The two groups are com-
parable in all aspects except for gender and the location
of CRC. Since there was no significant relationship be-
tween gender or the location of CRC and the survival
rate in the previous literature [18], our results suggest
that survival outcomes after pulmonary metastasectomy
were not compromised by a history of successful hepatic
metastasectomy.
Our findings are in line with previous studies regarding
the outcomes of combined hepatic and pulmonary metas-
tasectomies. Although some authors found that a previous
hepatic metastasectomy was associated with poor sur-
vival in patients undergoing pulmonary metastasect-
omy [7–10], most studies have reported that a history
of liver metastases at the time of pulmonary metasta-
sectomy was not a significant risk factor affecting sur-
vival, and that outcomes after combined hepatic and
pulmonary metastasectomies were similar to those after
hepatic metastasectomy alone or pulmonary metastasect-
omy alone [6, 8, 11–17]. The reported 5-year OS rates
ranged from 11 to 61 % after combined hepatic and pul-
monary metastasectomies [8, 11–17]. Ike et al. showed
that there was no significant difference in survival rates
between patients who underwent sequential hepatic and
pulmonary metastasectomies and those who underwent
pulmonary metastasectomy alone [16].
However, the role of metastasectomy in patients with
stage IV CRC are still controversial because these
encouraging outcomes are not based on prospective
randomized controlled trials comparing metastasectomy
with either medical treatment or observation alone [19].
Fig. 1 Comparison of overall survival between group HM + PM and group PM
Table 3 Summary of recurrence in the study population
Number of patients (%)
All patients
(n = 524)





Overall recurrence 286 (54.6) 58 (54.7) 228 (54.6) 0.975
Locoregional 20 (3.8) 4 (3.8) 16 (3.8) 0.979
Distant 248 (47.3) 52 (49.1) 196 (46.9) 0.69
Both 18 (3.6) 2 (2) 16 (4) 0.326
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Previously reported studies might have only included can-
didates regarded as suitable for pulmonary metastasect-
omy and excluded those who are not fit for pulmonary
metastasectomy [20]. In this context, the encouraging sur-
vival rate of patients undergoing hepatic metastasectomy
and pulmonary metastasectomy in the present study
might be attributed to the fact that selected candidates
have favorable prognostic factors rather than the benefit
from metastasectomy per se. Therefore, it is difficult to
prove whether our good results after combined hepatic
and pulmonary metastasectomies are due to metastasect-
omy or selection bias.
Nonetheless, the fact that the beneficial effect of
pulmonary metastasectomy in patients with a previous
hepatic metastasectomy has not been proved by
randomized studies does not necessarily mean that the
opportunity of surgery should be denied for patients
who could have benefitted from pulmonary metastasect-
omy. For patients with liver and lung metastases that
cannot be satisfactorily managed by palliative chemo-
therapy, it would be much more helpful to find out
which patient is most likely to benefit from pulmonary
metastasectomy. In previous studies, many authors tried
to elucidate various prognostic factors in patients
Fig. 2 Comparison of disease-free survival between group HM + PM and group PM
Table 4 Factors associated with overall survival and disease-free
survival on multivariate analyses for the entire patient population
Variable Overall survival Disease-free survival
HR 95 % CI P value HR 95 % CI P value
Age at PM 1.03 1.01–1.04 0.001 – – –
CRC pTstage 1.65 1.23–2.2 0.001 1.22 1.0–1.48 0.05
CRC pNstage 1.32 1.08–1.61 0.006 1.19 1.03–1.38 0.021
Previous HM 1.79 1.22–2.63 0.003 1.45 1.1–1.92 0.008
DFI (≥12months)a 0.68 0.47–0.94 0.02 0.63 0.49–0.81 <0.001
Multiple LM 2.28 1.6–3.24 <0.001 1.66 1.27–2.16 <0.001
Size of largest LMb 1.06 0.94–1.19 0.343 1.1 1.0–1.2 0.043
Non-anatomical PMc 0.63 0.45–0.89 0.009 – – –
VATS 0.82 0.6–1.14 0.24 0.67 0.53–0.85 0.001
Adjuvant CTx 0.58 0.42–0.82 0.002 – – –
HR hazard ratio, CI confidence interval, PM pulmonary metastasectomy, CRC
colorectal cancer, HM hepatic metastasectomy, pTstage pathologic T stage,
pNstage pathologic N stage, DFI disease-free interval, LM lung metastases,
VATS video-assisted thoracoscopic surgery, CTx chemotherapy
aDisease-free interval was calculated as the interval between the date of
colorectal cancer resection and the date of pulmonary metastasectomy
bThe long-axis diameter of the largest lung metastatic nodule was measured
cNon-anatomical pulmonary resection included precision excision of metastatic
nodules or wedge resection
Table 5 Factors associated with overall survival and disease-free
survival on multivariate analyses for group HM + PM
Variable Overall survival Disease-free survival
HR 95 % CI P value HR 95 % CI P value
Age at PM 3.77 1.48–9.59 0.005 1.31 0.68–2.52 0.44
DFI (≥12months)a 0.98 0.95–0.99 0.036 0.98 0.96–0.99 0.003
Multiple LM 3.97 1.53–10.4 0.005 2.0 1.04–3.87 0.039
Size of largest LMb 1.69 1.00–2.83 0.048 1.2 0.89–1.63 0.227
HR hazard ratio, CI confidence interval, PM pulmonary metastasectomy,
DFI disease-free interval, LM lung metastases
aDisease-free interval was calculated as the interval between the date of
colorectal cancer resection and the date of pulmonary metastasectomy
bThe long-axis diameter of the largest lung metastatic nodule was measured
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undergoing combined hepatic and pulmonary metasta-
sectomies, including number of metastatic lesions, DFI,
pretreatment CEA level, and mediastinal lymph node
involvement [6–17]. In the present study, a prognostic
factor analysis confined to group HM + PM revealed
that shorter DFI (<12 months) and number of lung me-
tastases were prognostic factors associated with worse
OS and DFS. This means that patients who have longer
DFI and small number of lung metastases are more
likely to benefit from pulmonary metastasectomy even
though they had a previous hepatic metastasectomy, and
surgical resection for lung metastases can be more
aggressively recommended for those patients.
Our study has several limitations. First, this is a retro-
spective study, which has many intrinsic drawbacks.
Second, as discussed above, this is a nonrandomized
study subject to selection bias. We should be cautious in
interpreting our results because our patients selected for
metastasectomy might have had inherent favorable prog-
nostic features. The encouraging survival after pulmon-
ary metastasectomy in overall patients and comparable
outcomes between the two groups might have come
from selection bias, not from the effect of treatment per
se. These limitations need to be overcome by prospect-
ive randomized trial. Third, there was a significant
difference in the number of patients between the two
groups. This difference should be considered when
interpreting our results from a statistical standpoint.
This may also be related to the fact that the number of
patients at risk after 4 or 5 years in group HM + PM
was relatively small compared with group PM, which
limits the validity of long-term survival comparison.
Conclusions
In conclusion, we retrospectively evaluated whether a
history of hepatic metastasectomy influences survival in
CRC patients undergoing pulmonary metastasectomy by
comparing treatment outcomes between patients with a
history of hepatic metastasectomy and those without.
We found that the long-term OS and DFS rates did not
differ between the two groups. Given that the two
groups are comparable, our findings suggest that a
history of successful hepatic metastasectomy does not
compromise survival in CRC patients undergoing
pulmonary metastasectomy. Therefore, we believe that
as long as liver metastasis is completely resected, there
is no reason to deny pulmonary metastasectomy when
patients have no unfavorable prognostic factors other
than a history of previous hepatic metastasectomy.
Based on prognostic factor analyses, patients who have
longer DFI and small number of lung metastases are
more likely to benefit from pulmonary metastasectomy
even after hepatic metastasectomy.
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